RT Journal Article
SR Electronic
T1 Monitoring Report: GLP-1 RA Prescribing Trends - March 2024 Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.18.24301500
DO 10.1101/2024.01.18.24301500
A1 Gratzl, Samuel
A1 Rodriguez, Patricia J
A1 Cartwright, Brianna M Goodwin
A1 Baker, Charlotte
A1 Do, Duy
A1 Stucky, Nicholas L
YR 2024
UL http://medrxiv.org/content/early/2024/04/18/2024.01.18.24301500.abstract
AB Background Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.Objective To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified patients who were prescribed a GLP-1-based medication between January 01, 2018 and March 31, 2024. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data are available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.Results 1,055,900 patients were prescribed a GLP-1 RA between January 2018 and March 2024, with 4,161,731 total prescriptions during this period. Among first-time prescriptions for which labeled use could be established, ADMs accounted for 85.0% and AOMs accounted for 15.0%. The most common first-time medication was semaglutide (n = 569,413). Among those with available data, 70.4% of first-time ADM prescriptions overall and 74.1% in December 2023 had a fill within 60 days. By comparison, 43.3% of first-time AOM prescriptions overall and 34.9% in December 2023 had a fill within 60 days.Competing Interest StatementAll authors are employees of Truveta, Inc.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Paragraph 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.